China's Medical Breakthrough: The First Drug to Revolutionize Rabies Prevention

Shenzhen, Monday, 22 June 2026.
On June 22, 2026, China approved the world’s first bispecific antibody drug for rabies prevention, Silevimig Injection. This groundbreaking innovation could save millions of lives annually, especially in developing regions where rabies remains a critical public health issue with a near 100% fatality rate. The drug’s unique dual-target approach aligns with WHO recommendations and promises easier administration, lower costs, and broader accessibility, potentially transforming global rabies treatment protocols.